Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03695926 · ClinicalTrials.gov registry record · Early Phase 1
Assessment of [18F]MNI-1054 as a Marker for LSD1
A Early Phase 1 study, sponsored by Invicro.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 4
- Enrollment target
NCT03695926 is a Early Phase 1 study that has completed, run by Invicro. The registered enrollment target is 4 participants.
The verdict
NCT03695926, a Early Phase 1 study, has completed, sponsored by Invicro.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
The primary objective of this protocol is to evaluate \[18F\]MNI-1054 as a Lysine-specific histone demethylase 1A (LSD1) enzyme targeted radiopharmaceutical.
Interventions
- DRUG [18F]MNI-1054
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2018-08-09 |
| Est. Completion | 2019-05-02 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03695926
The ClinicalTrials.gov registry entry for NCT03695926 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Invicro, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which [18F]MNI-1054 is the first listed.
NCT03695926 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03695926 about?
NCT03695926 is a clinical study titled "Assessment of [18F]MNI-1054 as a Marker for LSD1". The primary objective of this protocol is to evaluate \[18F\]MNI-1054 as a Lysine-specific histone demethylase 1A (LSD1) enzyme targeted radiopharmaceutical.
What is the current status of trial NCT03695926?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 4 participants. The study started on 2018-08-09. Estimated completion is 2019-05-02.
What interventions are being tested in trial NCT03695926?
The interventions under investigation include: [18F]MNI-1054 (DRUG).
Who is sponsoring clinical trial NCT03695926?
This trial is sponsored by Invicro, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.